SENATE BILL 306

By: **Senator Beidle** Introduced and read first time: January 13, 2025 Assigned to: Finance

Committee Report: Favorable with amendments Senate action: Adopted Read second time: February 22, 2025

CHAPTER _____

1 AN ACT concerning

Workers' Compensation – Prescription Drug and Pharmaceutical Services – Reimbursements

- FOR the purpose of requiring the State Workers' Compensation Commission to regulate
 fees and other charges for the reimbursement of prescription drugs and
 pharmaceutical services <u>under certain circumstances</u>; limiting reimbursements to a
 certain cost index or indexes; <u>requiring the Maryland Prescription Drug Affordability</u>
 <u>Board to conduct a certain study</u>; and generally relating to reimbursement for
- 9 prescription drugs and pharmaceutical services under workers' compensation law.
- 10 BY repealing and reenacting, with amendments,
- 11 Article Labor and Employment
- 12 Section 9–663
- 13 Annotated Code of Maryland
- 14 (2016 Replacement Volume and 2024 Supplement)

15 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 16 That the Laws of Maryland read as follows:

- 16 That the Laws of Maryland read as follows:
- 17

Article – Labor and Employment

18 9–663.

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.

<u>Underlining</u> indicates amendments to bill.

Strike out indicates matter stricken from the bill by amendment or deleted from the law by amendment.



^{19 (}a) (1) The Commission shall adopt regulations setting standards for the 20 assessment of fines under § 9–664 of this Part IX of this subtitle.

(2)1 The Commission may adopt regulations about: $\mathbf{2}$ (i) the provision of medicine and medical, nursing, and hospital 3 services to a covered employee; 4 (ii) payment for the medicine and services; and the exercise by the Chairman of the Commission of the powers $\mathbf{5}$ (iii) granted under § 9–662 of this subtitle. 6 7 (b) (1)The Commission may regulate fees and other charges for medical 8 services or treatment under this subtitle. 9 THE NOT LATER THAN SEPTEMBER 1, 2026, THE (2)**(I)** 10 COMMISSION SHALL **REGULATE FEES** AND OTHER CHARGES FOR THE 11 REIMBURSEMENT OF PRESCRIPTION DRUGS AND PHARMACEUTICAL SERVICES 12UNDER THIS SUBTITLE PROVIDED BY A PERSON WHO HOLDS A PHARMACY PERMIT UNDER TITLE 12, SUBTITLE 4 OF THE HEALTH OCCUPATIONS ARTICLE. 13 14**(II) REIMBURSEMENT UNDER SUBPARAGRAPH (I) OF THIS** PARAGRAPH SHALL BE LIMITED TO AN INDEX OR INDEXES BASED ON ACQUISITION 1516COST, CALCULATED ON A PER UNIT BASIS, AS OF THE DATE OF DISPENSING AND MAY 17**INCLUDE:** 18 1. **REASONABLE DISPENSING FEES; AND** 19 2. ANY OTHER PERCENTAGE INCREASE OR DECREASE 20DETERMINED BY THE COMMISSION. 21(III) THIS PARAGRAPH DOES NOT PROHIBIT AN INSURANCE 22CARRIER OR EMPLOYER FROM CONTRACTING WITH A PHARMACY BENEFITS MANAGER, A NETWORK OF PHARMACIES, OR DISPENSING PROVIDERS: 23241. FOR REIMBURSEMENT RATES DIFFERENT THAN 25THOSE ESTABLISHED BY THE COMMISSION; OR 262. TO USE A PRICING INDEX OR INDEXES DIFFERENT 27THAN THOSE SELECTED BY THE COMMISSION. 28(3) Each fee or other charge for medical service or treatment under this 29subtitle is limited to the amount that prevails in the same community for similar treatment 30 of an injured individual with a standard of living that is comparable to that of the covered

31 employee.

 $\mathbf{2}$

SENATE BILL 306

SENATE BILL 306

1	[(3)] (4)	At least once every 2 years, the Commission shall:
$\frac{2}{3}$	(i) r reasonableness; and	review its guide of medical and surgical fees for completeness and
4 5	(ii) r fees.	make appropriate revisions to the guide of medical and surgical
6	SECTION 2. AND E	<u>BE IT FURTHER ENACTED, That:</u>
7	(a) The Maryland	d Prescription Drug Affordability Board:
$\frac{8}{9}$		onduct a study on prescription drug affordability challenges asation claims that includes:
10 11		an overview of prescription drug prescribing and billing practices lized to the workers' compensation market;
$\begin{array}{c} 12 \\ 13 \end{array}$	(ii) <u>research into specific prescribing, billing, and dispensing</u> <u>practices, including:</u>	
$\begin{array}{c} 14 \\ 15 \end{array}$	<u>formulations of commonly</u>	<u>1. prescribing high cost formulations and compounded available drugs:</u>
$\begin{array}{c} 16 \\ 17 \end{array}$	2 provide services in the hea	2. <u>billing and dispensing from entities that do not bill or</u> <u>lth insurance market; and</u>
$\begin{array}{c} 18\\19\end{array}$	pricing metrics; and	<u>B.</u> <u>billing practices using billing codes without standardized</u>
$\begin{array}{c} 20\\ 21 \end{array}$	(iii) <u>making recommendations, if applicable, for policies to address</u> identified affordability challenges; and	
$22 \\ 23 \\ 24$	(2) <u>may require, subject to applicable federal and State laws, entities that</u> <u>pay, prescribe, bill, and dispense prescription drugs under workers' compensation claims</u> <u>to report information to the Board as necessary to complete the study.</u>	
25 26 27 28	(b) On or before March 1, 2026, the Prescription Drug Affordability Board shall report its findings and any recommendations to the Senate Finance Committee and the House Economic Matters Committee, in accordance with § 2–1257 of the State Government Article.	
29 30	SECTION 2 <u>3.</u> ANI	D BE IT FURTHER ENACTED, That this Act shall take effect

30 October July 1, 2025.